Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ColiFin in adult bronchiectasis patients with new asymptomatic Pseudomonas aeruginosa infection
DRKS00028518Phase 2Recruiting
- Sponsor
- Philipps-Universität Marburg
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bronchiectasis and Pseudomonal infection comparing ColiFin inhalation with Standard of care (no study drug) (2 arms). Started Jun 2022; status: recruiting.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on DRKS00028518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00028518.